Phase II Study of Human Lymphoblastoid Interferon in Patients with Multiple Myeloma
作者:
Edwin Cox,
John Laszlo,
Susan Krown,
David Mintzer,
Gregory Sarna,
期刊:
Journal of Biological Response Modifiers
(OVID Available online 1988)
卷期:
Volume 7,
issue 3
页码: 318-318
ISSN:0732-6580
年代: 1988
出版商: OVID
关键词: Human lymphoblastoid interferon;Multiple myeloma;Toxicity;Renal failure
数据来源: OVID
摘要:
Interferon has been reported to have activity in the treatment of multiple myeloma. We studied 24 myeloma patients treated with human lymphoblastoid interferon (Wellferon) by intramuscular injection twice weekly at an initial dose of 3 MU/M2 (three patients) or 15 MU/M2 (21 patients). One of 17 evaluable patients achieved a partial remission, three others were stable over a 16-week period of treatment, and 13 others had progressive disease. Subjective toxicity was frequent and substantial, particularly at the 15 MU dose level. Hematologic toxicity was mild and reversible. Two patients experienced acute renal failure. The low rate of response (69c) and substantial level of toxicity fail to support further exploration of these schedules of interferon as a single agent in myeloma.
点击下载:
PDF
(345KB)
返 回